Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA929)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 November 2023
Algorithm-based remote monitoring of heart failure risk data in people with cardiac implantable electronic devicesStatus:In developmentProgramme:Diagnostics guidanceExpected publication date: 22 August 2024
Empagliflozin for preventing cardiovascular events after acute myocardial infarction ID6240Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Chronic heart failure in adults: diagnosis and management - Pharmacological treatment of chronic heart failureStatus:In developmentProgramme:NICE guidelineExpected publication date: TBC
Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Virtual Wards for Heart FailureStatus:Awaiting developmentProgramme:Medical technologies guidanceExpected publication date: TBC